Publication date: 30/04/2018
MDxHealth SA ("MDxHealth, or the "Company"), (Euronext: MDXH.BR), today released its 2017 Annual Report and the invitation to its Annual General Shareholders' Meeting ("AGM") to be held on Thursday 31 May 2018 at 10.00 CEST, at Regus Brussels Zuid-Midi Railway Station, Avenue Fonsny 46, box 59, 1060 Brussels.
The 2017 Annual Report is available on the Company's website and outlines the Company's strategy, a review of its business and the 2017 consolidated financial statements.
In his letter to shareholders, Dr. Jan Groen, Chief Executive Officer of MDxHealth, commented: "2017 was an important year for the continuing development of MDxHealth as we look to establish ourselves as the world's leading urological molecular diagnostics company. The start of 2018 has been very encouraging and has brought further evidence illustrating the strength of our product offering."
In addition to the customary year-end resolutions, the AGM will be proposed to approve the following changes to the Board of Directors:
For further information on the agenda of the AGM, the proposed resolutions and candidate Directors, please see the Company's website.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.